Home/Luxa Biotechnology/Sally Temple, Ph.D.

ST

Sally Temple, Ph.D.

Founder, Chief Scientific Officer

Luxa Biotechnology

Therapeutic Areas

Ophthalmology Retinal Diseases

Luxa Biotechnology Pipeline

Drug	Indication	Phase
RPESC-RPE-4W	Dry Age-Related Macular Degeneration (AMD) / Geographic Atrophy	Phase 1/2a

Leadership Team at Luxa Biotechnology

Keith E. Dionne, Ph.D.

Chief Executive Officer

Jeffrey Stern, Ph.D., M.D.

Founder, Chief Medical Officer

Founder, Co-CEO

View full Luxa Biotechnology profile